[1. Rydеn L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res. 2014;11(3):133-73.10.1177/147916411452554824800783]Search in Google Scholar
[2. Hoch E, Rusu V, Schreiber SL, Florez JC, Jacobs SB, Lander ES. Type 2 diabetes-associated variants disrupt function of SLC16A11, a proton-coupled monocarboxylate transporter, through two distinct mechanisms, Faseb J. 2017; 31.]Search in Google Scholar
[3. Cowan J. Overview of Type 2 Diabetes. Essentials of SGLT2 Inhibitors in Diabetes, Springer, 2017.10.1007/978-3-319-43296-0_1]Search in Google Scholar
[4. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care 2003; 26:881–5.10.2337/diacare.26.3.88112610053]Search in Google Scholar
[5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813–20.10.1038/414813a11742414]Search in Google Scholar
[6. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106:2067–72.10.1161/01.CIR.0000034509.14906.AE12379575]Search in Google Scholar
[7. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295:1681–7.10.1001/jama.295.14.168116609090]Search in Google Scholar
[8. Omotayo EO, Gurtu S, Sulaiman SA, Wahab MSA, Sirajudeen K, Salleh MSM. Hypoglycemic and antioxidant effects of honey supplementation in streptozotocin-induced diabetic rats, Int. J. Vitam. Nutr. Res. 2010; 80(1):74-82.10.1024/0300-9831/a000008]Search in Google Scholar
[9. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003; 17(1):24-38.10.1002/jbt.1005812616644]Open DOISearch in Google Scholar
[10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.10.2337/dc08-9025260681318945920]Search in Google Scholar
[11. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011; 15:298–308.10.4103/2230-8210.85583319377922029001]Search in Google Scholar
[12. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13:7–18.10.1111/j.1463-1326.2010.01306.x21114598]Open DOISearch in Google Scholar
[13. Blech S, Ludwig-Schwellinger E, Grаfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010; 38:667–78.10.1124/dmd.109.031476]Search in Google Scholar
[14. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24:79–83.10.1016/j.jdiacomp.2009.01.004]Search in Google Scholar
[15. Reed, M.J., Meszaros, K., Entes, L.J., Claypool, M.D., Pinkett, J.G., Gadbois, T.M., and Reaven, G.M. 2000. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism 49:1390-1394.10.1053/meta.2000.17721]Search in Google Scholar
[16. Brondum, E., Nilsson, H., and Aalkjaer, C. 2005. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm. Metab. Res. 37:56-60.10.1055/s-2005-861370]Search in Google Scholar
[17. Auclair C, Voisin E (1985). Nitroblue tetrazolium reduction. In: Greenvvald RA (ed) Handbook of methods for oxygen radical research. CRC Press Une, Boca Raton, pp 123–32.]Search in Google Scholar
[18. Pick E, Keisari Y. A simple colorimetric method for the measurment of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38:161–70.10.1016/0022-1759(80)90340-3]Open DOISearch in Google Scholar
[19. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal Biochem 1982; 26: 131–138.10.1016/0003-2697(82)90118-X]Open DOISearch in Google Scholar
[20. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351–8.10.1016/0003-2697(79)90738-3]Search in Google Scholar
[21. Aebi H. Catalase in vitro. Methods in Enzymology. 1984; 105: 121-6.10.1016/S0076-6879(84)05016-3]Search in Google Scholar
[22. Beutler E. Superoxide dismutase. In: Beutler E, eds. Red Cell Metabolism. A Manual of Biochemical Methods. Philadelphia, Grune & Stratton:PA; 1984: 83-5.]Search in Google Scholar
[23. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood. Glutathione. J Lab Clin Med. 1963; 61: 882–8.]Search in Google Scholar
[24. Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114(3):525-31.10.1002/jcb.2440222991242]Search in Google Scholar
[25. Rehman K, Akash MSH. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked? J Cell Biochem. 2017;118(11):3577-85.10.1002/jcb.2609728460155]Open DOISearch in Google Scholar
[26. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with under-weight, overweight, and obesity. JAMA. 2007;298(17):2028-37.10.1001/jama.298.17.2028]Search in Google Scholar
[27. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45(1):85-96.10.1007/s125-002-8248-z]Open DOISearch in Google Scholar
[28. Shin CS, Moon BS, Park KS, Kim SY, Park SJ, Chung MH, Lee HK. Serum 8-hydroxy-guanine levels are increased in diabetic patients. Diabetes Care. 2001;24(4):733-7.10.2337/diacare.24.4.733]Search in Google Scholar
[29. Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H. The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit. 2008;14(2):CR97-101.]Search in Google Scholar
[30. Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222.10.3390/biom5010194]Search in Google Scholar
[31. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol.2007;39(1):44-84.10.1016/j.biocel.2006.07.001]Open DOISearch in Google Scholar
[32. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2016;24(5):547-53.10.1016/j.jsps.2015.03.013]Search in Google Scholar
[33. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2010;20(1):72-7.10.1016/j.numecd.2009.06.00219747805]Open DOISearch in Google Scholar
[34. Pеrez-Matute P, Zulet MA, Martínez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol. 2009;9(6):771-9.10.1016/j.coph.2009.08.005]Open DOISearch in Google Scholar
[35. Murakami K, Kondo T, Ohtsuka Y, Fujiwara Y, Shimada M, Kawakami Y. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism. 1989;38(8):753-8.256966110.1016/0026-0495(89)90061-9]Search in Google Scholar
[36. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-12.10.1001/jama.281.21.200510359389]Search in Google Scholar
[37. Fisman EZ, Motro M, Tenenbaum A. Non-insulin anti-diabetic therapy in cardiac patients: current problems and future prospects. Adv Cardiol. 2008; 45:154-170.10.1159/00011519318230961]Search in Google Scholar
[38. Kottenberg E, Thielmann M, Kleinbongard P, Frey UH, Heine T, Jakob H, Heusch G, Peters J. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. Acta Anaesthesiol Scand. 2014;58(4):453-62.10.1111/aas.1227824548338]Search in Google Scholar
[39. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes and vascular disease research. 2006; 3(3): 159-65.10.3132/dvdr.2006.02417160910]Search in Google Scholar
[40. Tatosian DA, Guo Y, Schaeffer AK, Gaibu N, Popa S, Stoch A, Langdon RB, Kauh EA. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy. 2013; 4(2): 431-42.10.1007/s13300-013-0045-8388931724163113]Search in Google Scholar
[41. Sherif IO, Al-Shaalan NH. Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway. Oxid Med Cell Longev. 2018; 2018:3509091.10.1155/2018/3509091620418230405876]Search in Google Scholar
[42. El-Kashef DH, Serrya MS. Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice. Life Sci. 2019; 228:266-273.10.1016/j.lfs.2019.05.01931077717]Search in Google Scholar
[43. Kelany ME, Hakami TM, Omar AH, Abdallah MA. Combination of Sitagliptin and Insulin against Type 2 Diabetes Mellitus with Neuropathy in Rats: Neuroprotection and Role of Oxidative and Inflammation Stress. Pharmacology. 2016;98(5-6):242-250.10.1159/00044804327449930]Search in Google Scholar
[44. Helal MG, Zaki MMAF, Said E. Nephroprotective effect of saxagliptin against gentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatory and anti-apoptic effects. Life Sci. 2018; 208:64-71.10.1016/j.lfs.2018.07.02130012474]Search in Google Scholar
[45. Liu Y, Zhang Z, Chen R, Sun J, Chen H. Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34(6):862-8.24968846]Search in Google Scholar
[46. Refaat R, Sakr A, Salama M, El Sarha A. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug Dev Res. 2016;77(6):300-9.10.1002/ddr.2132427520857]Search in Google Scholar